Archive - February 2019
Lynparza successful in pancreatic cancer trial
Biogen & Alkermes get NDA for MS drug
FDA Breakthrough Therapy Designation for Pompe disease drug
Novartis to licence Akcea’s lipoprotein lowering drug
Brilinta hits targets in PhIII cardiovascular/diabetes trial
Boehringer Ingelheim appoints new chief medical officer
FDA and Flatiron extend real world evidence collaboration
Lynparza scores against pancreatic cancer
